Kaleido is a small, discreet, customizable insulin patch pump built by Dutch medtech company ViCentra to make living with diabetes less of a burden. Designed to look and feel like a lifestyle product rather than a clinical device, Kaleido pairs with Diabeloop's self-learning algorithm and the Dexcom CGM to enable hybrid closed-loop, app-controlled insulin delivery. With more than 3,500 users in Europe and an $85M+ Series D raised in 2025, the company is scaling manufacturing of its next-generation Kaleido 2 and preparing for entry into the United States.

Thomas (Tom) Arnold is the Chief Executive Officer of ViCentra, the Dutch maker of Kaleido, billed as one of the smallest, lightest and most precise insulin patch pumps in its class. Appointed in February 2025 after nearly 25 years across Medtronic, PROCEPT BioRobotics, Boston Scientific and Sorin Group, he is steering ViCentra's smartphone-controlled automated insulin delivery system into European markets and toward a US entry, backed by financing that has grown from $85M to $98M.